Advocacy intelligence hub — real-time data for patient organizations
POTELIGEO: FDA approved
POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S®zary syndrome (SS) after at least one prior systemic therapy.
Ontak: FDA approved
Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Ontak
Eisai, Inc.
POTELIGEO
(mogamulizumab)Orphan drugKyowa Kirin Pharmaceutical Development Inc.
Chemokine Receptor Type 4 Interaction [EPC]
12.1 Mechanism of Action Mogamulizumab-kpkc is a defucosylated, humanized IgG1 kappa monoclonal antibody that binds to CCR4, a G protein-coupled recep...
Ontak
(denileukin diftitox)Orphan drugEisai, Inc.
CD25-directed Cytotoxin [EPC]
12.1 Mechanism of Action Denileukin diftitox-cxdl is a fusion protein designed to direct the cytocidal action of diphtheria toxin (DT) to cells which ...
Browse all Indolent primary cutaneous T-cell lymphoma news →
Steven Horwitz, MD
Memorial Sloan Kettering Cancer Center
Thomas C. Shea, MD
UNC Lineberger Comprehensive Cancer Center
Reem Karmali, MD, MD
Northwestern University
📍 CHICAGO, IL
Amy Kimball, MD, PhD
University of Maryland Greenebaum Cancer Center
Mack Mabry, MD
AbbVie
Sho Ma, MD, PhD, L Acupuncturist
Northwestern University & Robert H Lurie Comprehensive Cancer Center
📍 SEATTLE, WA
View all Indolent primary cutaneous T-cell lymphoma specialists →